What therapeutic areas does PERRIGO R AND D focus on?

PERRIGO R AND D focuses primarily on Gastroenterology and Infectious Disease and 1 other therapeutic areas.

Data updated: Jul 17, 2026

PERRIGO R AND D

Q: What drugs does PERRIGO R AND D make?

PERRIGO R AND D has 26 FDA-approved drugs including NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.

Generics

Gastroenterology Infectious Disease Cardiovascular

PERRIGO R AND D is a generic drug manufacturer focused on Gastroenterology, Infectious Disease, Cardiovascular.

2005

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

PERRIGO R AND D's Key Drugs

PERRIGO R AND D's core commercial portfolio centers on NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, spanning Gastroenterology and Infectious Disease — its most strategically important drugs approved in the last 15 years.

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

Immunology

Approved 2018

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

Pain

Approved 2014

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

Respiratory

Approved 2015

PERRIGO R AND D's Recent FDA Approvals

PERRIGO R AND D secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

PERRIGO R AND D's Therapeutic Areas

PERRIGO R AND D's approved drugs and pipeline span 3 therapeutic areas, led by Gastroenterology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 50%

3 drugs

Infectious Disease 33%

2 drugs

Cardiovascular 17%

1 drugs

PERRIGO R AND D's Top Competitors

PERRIGO R AND D's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, WAYLIS THERAP, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

APOTHECON specialty

Infectious Disease, Cardiovascular, Gastroenterology

WAYLIS THERAP big-pharma

Cardiovascular, Infectious Disease, Gastroenterology

Merck big-pharma

Infectious Disease, Cardiovascular

WARNER CHILCOTT big-pharma

Cardiovascular, Gastroenterology, Infectious Disease

Baxter specialty

Infectious Disease, Cardiovascular